Children and adolescents with cystic fibrosis (CF) continue to experience mental health and behavioral concerns despite treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor), according to a recent study. Caregiver anxiety and depression were also found to be associated with mental health and behavioral symptoms in their children, highlighting the importance of considering caregiver mental health in CF care. […]
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.